mitochondrial translational release factor 1 like pseudogene 1Genealiases: []
Q-omics provides the consensus-scored MTRF1LP1 profile across patient tissues and cancer cell-line models. MTRF1LP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTRF1LP1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, MTRF1LP1 RNA expression shows 9,339 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where MTRF1LP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRF1LP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRF1LP1 survival associations across molecular data types. MTRF1LP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRF1LP1 RNA expression–survival associations across cancer types. High MTRF1LP1 expression shows unfavorable associations in MESO, DLBC, UVM, ACC and LUAD, but favorable associations in UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MTRF1LP1 RNA expression.
This table summarizes MTRF1LP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTRF1LP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRF1LP1 shows lower tumor expression in HNSC and BRCA and higher tumor expression in CHOL and KICH. The HNSC box plot shows higher MTRF1LP1 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p = .029).
This table shows molecular features associated with MTRF1LP1 in patient tissues and cancer cell lines. In patient samples, MTRF1LP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
